Caris
Caris Life Sciences Raises $168M to Support Continued Platform Expansion
The financing included participation from existing and new investors and is expected to support the firm's efforts to bring its precision medicine tests to as many patients as possible.
Labcorp, University Health System Pay $388K to Resolve False Claim Allegations
The government alleges Labcorp and UHS delayed submission of orders for tests by Caris Life Sciences to enable improper billings to Medicare for those tests.
Caris Life Sciences Expands Access to Urologic Cancer Tests Through Deal With Lumea
The firms agreed to make Caris' whole-exome and whole-transcriptome sequencing tests available through Lumea's BxLink digital pathology software.
Caris Life Sciences CDx Assay Nabs FDA Approval
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
Caris Life Sciences, EDX Medical Ink Molecular Profiling Distribution Agreement
EDX Medical has the exclusive rights to distribute Caris' portfolio of molecular profiling services throughout the UK and four Nordic countries.